Thomas Castellano
Director of Finance/CFO presso ABZENA PLC
Patrimonio netto: 708 165 $ in data 31/03/2024
Profilo
Attualmente, Thomas P. Castellano è Global Vice President-Operational Finance presso Catalent, Inc. È anche nel consiglio di amministrazione di Catalent France Beinheim SA. Il signor Castellano ha conseguito una laurea e un MBA presso la Seton Hall University.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
CATALENT INC
0.01% | 04/12/2023 | 12 545 ( 0.01% ) | 708 165 $ | 31/03/2024 |
Posizioni attive di Thomas Castellano
Società | Posizione | Inizio |
---|---|---|
ABZENA PLC | Director of Finance/CFO | 05/06/2023 |
Catalent France Beinheim SA
Catalent France Beinheim SA Pharmaceuticals: MajorHealth Technology Catalent France Beinheim SA is engaged in softgel development and manufacturing operations. It offers formulation development and manufacturing services for controlled substances, highly potent compounds, and hormones. The firm’s technologies include optiform® solution suite, optigel™ bio, and rp scherer softgel technology. The company was founded on May 3, 1965 and is headquartered in Beinheim, France. | Director/Board Member | - |
Catalent Belgium Holding SA | Director/Board Member | 05/08/2021 |
Precedenti posizioni note di Thomas Castellano
Società | Posizione | Fine |
---|---|---|
CATALENT, INC. | Director of Finance/CFO | 13/04/2023 |
Formazione di Thomas Castellano
Seton Hall University | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
CATALENT, INC. | Health Technology |
Aziende private | 3 |
---|---|
Catalent Belgium Holding SA | |
Catalent France Beinheim SA
Catalent France Beinheim SA Pharmaceuticals: MajorHealth Technology Catalent France Beinheim SA is engaged in softgel development and manufacturing operations. It offers formulation development and manufacturing services for controlled substances, highly potent compounds, and hormones. The firm’s technologies include optiform® solution suite, optigel™ bio, and rp scherer softgel technology. The company was founded on May 3, 1965 and is headquartered in Beinheim, France. | Health Technology |
Abzena Ltd.
Abzena Ltd. BiotechnologyHealth Technology Abzena Ltd. engages in the provision of proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products. It offers antibody discover and candidate screening, immunology and immunogenicity assessment, antibody and protein engineering, bio conjugation, custom synthesis of cytotoxic payloads, reagents, and other small molecules, manufacture of payload linkers, development of manufacturing cell lines, and manufacture of biopharmaceuticals. The company was founded by Sunil Shaunak in 2001 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
- Borsa valori
- Insiders
- Thomas Castellano